Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 36 articles: HTML format Text format

Single Articles

September 2017
1. BARNETT R
   Lung cancer.
   Lancet. 2017;390:928.
   PubMed     Text format    
   
   
   August 2017
2. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
   Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
   Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
   PubMed     Text format     Abstract available
   
   
   
3. JENKINS BJ
   Potential efficacy of interleukin-1beta inhibition in lung cancer.
   Lancet. 2017 Aug 25. pii: S0140-6736(17)32289.
   PubMed     Text format    
   
   
   May 2017
4. ROSS RJ, Mann NC
   Synchronous distal phalangeal metastases from primary non-small-cell lung cancer.
   Lancet. 2017 May 25. pii: S0140-6736(17)31288.
   PubMed     Text format    
   
   
   
5. HIDA T, Nokihara H, Kondo M, Kim YH, et al
   Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
   Lancet. 2017 May 10. pii: S0140-6736(17)30565.
   PubMed     Text format     Abstract available
   
   
   
6. GAINOR JF, Shaw AT
   J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
   Lancet. 2017 May 10. pii: S0140-6736(17)31074.
   PubMed     Text format    
   
   
   April 2017
7. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
   Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
   Lancet. 2017;389:1395-1396.
   PubMed     Text format    
   
   
   
8. ZHU J, Kang M, Fan X
   Whole brain radiotherapy for non-small cell lung cancer.
   Lancet. 2017;389:1395.
   PubMed     Text format    
   
   
   
9. CAGNEY DN, Alexander BM, Aizer AA
   Whole brain radiotherapy for non-small cell lung cancer.
   Lancet. 2017;389:1394-1395.
   PubMed     Text format    
   
   
   January 2017
10. SORIA JC, Tan DS, Chiari R, Wu YL, et al
    First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30123.
    PubMed     Text format     Abstract available
    
    
    
11. SOLOMON B
    First-line treatment options for ALK-rearranged lung cancer.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30124.
    PubMed     Text format    
    
    
    December 2016
12. LEDUC C, Quoix E
    Programmed death of chemotherapy in non-small-cell lung cancer?
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32535.
    PubMed     Text format    
    
    
    
13. RITTMEYER A, Barlesi F, Waterkamp D, Park K, et al
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32517.
    PubMed     Text format     Abstract available
    
    
    October 2016
14. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available
    
    
    
15. ZHANG L, Huang Y, Hong S, Yang Y, et al
    Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2016;388:1883-1892.
    PubMed     Text format     Abstract available
    
    
    September 2016
16. SCHILDGEN V, Schildgen O
    Routine molecular profiling of patients with NSCLC.
    Lancet. 2016;388:1054.
    PubMed     Text format    
    
    
    
17. HIRSCH FR, Suda K, Wiens J, Bunn PA Jr, et al
    New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Lancet. 2016;388:1012-24.
    PubMed     Text format     Abstract available
    
    
    
18. HILEY CT, Le Quesne J, Santis G, Sharpe R, et al
    Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.
    Lancet. 2016;388:1002-11.
    PubMed     Text format     Abstract available
    
    
    
19. MULVENNA P, Nankivell M, Barton R, Faivre-Finn C, et al
    Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiori
    Lancet. 2016 Sep 2. pii: S0140-6736(16)30825.
    PubMed     Text format     Abstract available
    
    
    August 2016
20. HIRSCH FR, Scagliotti GV, Mulshine JL, Kwon R, et al
    Lung cancer: current therapies and new targeted treatments.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)30958.
    PubMed     Text format     Abstract available
    
    
    
21. THE LANCET
    Lung cancer: despite advances, prevention is still best.
    Lancet. 2016;388:533.
    PubMed     Text format    
    
    
    July 2016
22. YAO JC, Voi M, Rouyrre N, Singh S, et al
    Everolimus in ileum neuroendocrine tumours - Authors' reply.
    Lancet. 2016;388:236-7.
    PubMed     Text format    
    
    
    
23. WALTER T, Lombard-Bohas C
    Everolimus in ileum neuroendocrine tumours.
    Lancet. 2016;388:236.
    PubMed     Text format    
    
    
    May 2016
24. RUSSELL P, Floridis J
    Hypertrichosis lanuginosa acquisita: a rare dermatological disorder.
    Lancet. 2016;387:2035.
    PubMed     Text format    
    
    
    April 2016
25. HORNLUND A
    Clarification regarding ethical review of Paolo Macchiarini's research.
    Lancet. 2016;387:1816.
    PubMed     Text format    
    
    
    
26. 
    Expression of concern--Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
    Lancet. 2016;387:1359.
    PubMed     Text format    
    
    
    March 2016
27. SMIT EF, van den Heuvel MM
    PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
    Lancet. 2016 Mar 10. pii: S0140-6736(16)00700.
    PubMed     Text format    
    
    
    
28. FEHRENBACHER L, Spira A, Ballinger M, Kowanetz M, et al
    Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Lancet. 2016 Mar 9. pii: S0140-6736(16)00587.
    PubMed     Text format     Abstract available
    
    
    
29. CLAESSON-WELSH L, Hansson GK
    Tracheobronchial transplantation: The Royal Swedish Academy of Sciences' concerns.
    Lancet. 2016;387:942.
    PubMed     Text format    
    
    
    
30. YAO JC, Fazio N, Singh S, Buzzoni R, et al
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
    Lancet. 2016;387:968-77.
    PubMed     Text format     Abstract available
    
    
    
31. OBERG K
    Universal everolimus for malignant neuroendocrine tumours?
    Lancet. 2016;387:924-6.
    PubMed     Text format    
    
    
    January 2016
32. MACCHIARINI P
    Tracheobronchial transplantation.
    Lancet. 2016;387:339.
    PubMed     Text format    
    
    
    
33. ROSELL R, Karachaliou N
    Large-scale screening for somatic mutations in lung cancer.
    Lancet. 2016 Jan 14. pii: S0140-6736(15)01125.
    PubMed     Text format    
    
    
    
34. BARLESI F, Mazieres J, Merlio JP, Debieuvre D, et al
    Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
    Lancet. 2016 Jan 14. pii: S0140-6736(16)00004.
    PubMed     Text format     Abstract available
    
    
    December 2015
35. MOK TS, Loong HH
    Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01308.
    PubMed     Text format    
    
    
    
36. HERBST RS, Baas P, Kim DW, Felip E, et al
    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01281.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: